B&K Corporation Limited (HKG:2396)

Market Cap	870.67M
Revenue (ttm)	285.25K -44.7%
Net Income	-199.59M
EPS	-2.00
Shares Out	117.66M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,800
Average Volume	53,870
Open	7.66
Previous Close	7.66
Day's Range	7.40 - 7.68
52-Week Range	6.82 - 37.20
Beta	n/a
RSI	32.37
Earnings Date	Mar 30, 2026

About B&K Corporation

B&K Corporation Limited operates as a biopharmaceutical company developing therapies with an emphasis on protein drugs for indications with medical needs and market opportunities in China. The company primarily focuses on the discovery, development, and commercialization of therapies for wound healing, currently platelet-derived growth factor (“PDGF”) drugs. The company’s pipeline comprised two Core Products including Pro-101-1 for the treatment of deep second-degree thermal burns, which has completed the statistical data analysis for Phase IIb...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 100
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2396

Financial Performance

Financial numbers in CNY